| General Information | |
|---|---|
| ZINC ID | ZINC000299830789 |
| Molecular Weight (Da) | 462 |
| SMILES | Cc1ccc(Cn2nc(C(=O)N[C@H]3C[C@@H](C)CC[C@@H]3C(C)C)c3c2-c2c(C)csc2C3)cc1 |
| Molecular Formula | C28N3O1S1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 137.414 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| LogP | 6.735 |
| Activity (Ki) in nM | 158.489 |
| Polar Surface Area (PSA) | 75.16 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.82274055 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 16 |
| Fraction csp3 | 0.5 |
| Ilogp | 4.58 |
| Xlogp3 | 7.02 |
| Wlogp | 6.37 |
| Mlogp | 4.67 |
| Silicos-it log p | 7.08 |
| Consensus log p | 5.94 |
| Esol log s | -7.09 |
| Esol solubility (mg/ml) | 0.0000377 |
| Esol solubility (mol/l) | 8.17E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.41 |
| Ali solubility (mg/ml) | 0.00000178 |
| Ali solubility (mol/l) | 3.85E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.21 |
| Silicos-it solubility (mg/ml) | 0.00000282 |
| Silicos-it solubility (mol/l) | 6.11E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.13 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 5.18 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.339 |
| Logd | 5.988 |
| Logp | 6.789 |
| F (20%) | 0.06 |
| F (30%) | 0.005 |
| Mdck | - |
| Ppb | 99.37% |
| Vdss | 2.084 |
| Fu | 1.21% |
| Cyp1a2-inh | 0.096 |
| Cyp1a2-sub | 0.793 |
| Cyp2c19-inh | 0.912 |
| Cyp2c19-sub | 0.845 |
| Cl | 9.478 |
| T12 | 0.011 |
| H-ht | 0.804 |
| Dili | 0.875 |
| Roa | 0.519 |
| Fdamdd | 0.798 |
| Skinsen | 0.045 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.853 |
| Bcf | 1.488 |
| Igc50 | 4.703 |
| Lc50 | 6.581 |
| Lc50dm | 5.2 |
| Nr-ar | 0.017 |
| Nr-ar-lbd | 0.06 |
| Nr-ahr | 0.067 |
| Nr-aromatase | 0.901 |
| Nr-er | 0.595 |
| Nr-er-lbd | 0.668 |
| Nr-ppar-gamma | 0.86 |
| Sr-are | 0.409 |
| Sr-atad5 | 0.004 |
| Sr-hse | 0.593 |
| Sr-mmp | 0.875 |
| Sr-p53 | 0.879 |
| Vol | 489.26 |
| Dense | 0.943 |
| Flex | 0.231 |
| Nstereo | 3 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.375 |
| Synth | 3.847 |
| Fsp3 | 0.5 |
| Mce-18 | 96.667 |
| Natural product-likeness | -0.959 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |